title: Recombinant human erythropoietin increases interleukin-1 beta production in cultured peripheral blood mononuclear cells from patients resistant to recombinant human erythropoietin therapy.
authors.forename: A
authors.initials: A
authors.lastname: Takemasa
authors.forename: N
authors.initials: N
authors.lastname: Yorioka
authors.forename: T
authors.initials: T
authors.lastname: Ito
authors.forename: K
authors.initials: K
authors.lastname: Yamashita
authors.forename: H
authors.initials: H
authors.lastname: Oda
authors.forename: M
authors.initials: M
authors.lastname: Yamakido
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000097:blood / Q000188:drug therapy; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007375:Interleukin-1 / Q000096:biosynthesis*; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D007375:Interleukin-1; D011994:Recombinant Proteins; D004921:Erythropoietin